Category - Markets

Ladenburg Thalmann launched coverage of Tocagen (NASDAQ: TOCA) with a “buy” rating and $20 price target. The stock closed at $8.81 on June 26. TOCA is developing a novel viral gene therapy for cancer and has developed a...

Analysts for Stifel and Canaccord Genuity raised their price targets for AtriCure (NASDAQ:ATRC) after an analyst day meeting highlighted the significant penetration opportunity in the atrial fibrillation (AF) market...

Maxim Group initiated coverage of IntelGenx (OTCQX:IGXT; TSXV:IGX) with a “buy” rating and price target of $3. The stock closed at 78 cents on June 26. Analyst Jason McCarthy writes that the company’s VersaFilm is a...

H.C. Wainwright initiated coverage of Avenue Therapeutics (NASDAQ:ATXI) with a “buy” rating and price target of $11. The stock closed at $3.77 on June 25. Avenue Therapeutics is focused on the acute care hospital...

H.C. Wainwright launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $6 price target. The stock closed at $2.22 on June 25. The company’s immunotherapy approach for the treatment of tumors is...

Roth Capital Partners initiated coverage of Soleno Therapeutics (NASDAQ:SLNO) with a “buy” rating and $14 price target. The stock closed at $2.32 on June 21. Soleno’s focus is on Prader-Wili Syndrome (PWS), a rare...

Roth Capital Partners initiated coverage of Evofem Biosciences (NASDAQ:EVFM) with a “buy” rating and $15 price target. The stock closed at $3.30 on June 19. Analyst Yasmeen Rahimi writes that the time is ripe for...

Echelon Wealth Partners hiked its price target for Neptune Wellness Solutions (TSX, NASDAQ:NEPT) to $8 from $5.25 after the company struck a strategic medical cannabis oil agreement with Canopy Growth (TSX:WEED). Shares...

H.C. Wainwright initiated coverage of Arcadia Biosciences (NASDAQ:RKDA) with a “buy” rating and $20 price target. The stock closed at $8.16 on June 18. Arcadia has a track record in the generation of productivity traits...

BTIG downgraded Helius Medical Technologies (NASDAQ:HSDT) to “neutral” from “buy” but maintained its $14 price target, saying it is uneasy about regulatory and fundraising timelines. The stock closed at $12.87 on June...